Apixaban in patients with atrial fibrillation and acute coronary syndrome in elective percutaneous coronary intervention: what did the subanalysis of the AUGUSTUS trial add to our understanding?

The article is devoted to the results of the subanalysis published after release of the AUGUSTUS trial. The most important conclusion of the parent trial is the evidence that weekly aspirin therapy is sufficient to prevent thrombotic complications in the majority of patients with AF and ACS, as well as those undergoing elective PCI, and that aspirin therapy can be extended up to 1 month after PCI only in a part of patients with additional risk factors for ischemic events and a low risk of bleeding. Four years have passed since the publication of the AUGUSTUS trial results, and all subsequent subanalyses of the trial confirmed its results. The safety and efficacy advantages of apixaban over warfarin were shown to be independent of renal function and consistent with the overall trial results. The advantages of apixaban and the association of aspirin with bleeding were similar in both stroke and non-stroke patients with AF and were dose-independent when a dose was reduced to 2.5 mg twice in accordance with the reduction criteria. The advantages of apixaban over warfarin lasted regardless of time spent in the therapeutic range in the warfarin group. The advantages of apixaban over warfarin and the association of long-term intake of aspirin with bleeding rates persisted in patients with high and low baseline risk of bleeding and stroke. All subanalyses of the AUGUSTUS trial confirmed the efficacy and safety of apixaban, as well as the option to discontinue aspirin at the outpatient stage in the majority of patients with AF, who underwent elective PCI or ACS.

1. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R et al.; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–1524. https://doi.org/10.1056/NEJMoa1817083.

2. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–2434. https://doi.org/10.1056/NEJMoa1611594.

3. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF et al. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation. 2020;141(9):781–783. https://doi.org/10.1161/CIRCULATIONAHA.119.044584.

4. Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG et al. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation. 2020;141(20): 1618–1627. https://doi.org/10.1161/CIRCULATIONAHA.120.046534.

5. Hijazi Z, Alexander JH, Li Z, Wojdyla DM, Mehran R, Granger CB et al. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2021;143(12):1215–1223. https://doi.org/10.1161/CIRCULATIONAHA.120.051020.

6. Bahit MC, Vora AN, Li Z, Wojdyla DM, Thomas L, Goodman SG et al. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. JAMA Cardiol. 2022;7(7):682–689. https://doi.org/10.1001/jamacardio.2022.1166.

7. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L et al.; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503–511. https://doi.org/10.1016/S1474-4422(12)70092-3.

8. Fudim M, Lopes R, Wojdyla D, Mehran R, Khan M, Granger C et al. Abstract 11994: Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2022;146:A11994. https://doi.org/10.1161/circ.146.suppl_1.11994.

9. Harrington J, Hellkamp A, Alexander J, Mehran R, Granger C, Goodman S et al. Benefits of Apixaban over Warfarin are Preserved lndependent of Warfarin Time in Therapeutic Range: Insight from the AUGUSTUS Trial. Circulation. 2022;146:A13168. https://doi.org/10.1161/circ.146.suppl_1.13168.

10. van Rein N, Heide-Jorgensen U, Lijfering WM, Dekkers OM, Sorensen HT, Cannegieter SC. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation. 2019;139:775–786. https://doi.org/10.1161/CIRCULATIONAHA.118.036248.

11. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.

12. Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE et al. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. J Am Coll Cardiol. 2022;79(5):417–427. https://doi.org/10.1016/j.jacc.2021.11.035.